Per Hall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5096218/publications.pdf

Version: 2024-02-01

256 papers 27,843 citations

62 h-index 154 g-index

267 all docs

267
docs citations

times ranked

267

39710 citing authors

#	Article	IF	Citations
1	Interval breast cancer is associated with interferon immune response. European Journal of Cancer, 2022, 162, 194-205.	1.3	3
2	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	2.0	6
3	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	2.2	15
4	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744.	3.4	51
5	Estimating Distributions of Breast Cancer Onset and Growth in a Swedish Mammography Screening Cohort. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 569-577.	1.1	6
6	Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer. Translational Oncology, 2022, 17, 101339.	1.7	1
7	A Swedish Genome-Wide Haplotype Association Analysis Identifies a Novel Breast Cancer Susceptibility Locus in 8p21.2 and Characterizes Three Loci on Chromosomes 10, 11 and 16. Cancers, 2022, 14, 1206.	1.7	1
8	Risk of heart disease following treatment for breast cancer – results from a population-based cohort study. ELife, 2022, 11, .	2.8	11
9	A Genome-Wide Gene-Based Gene–Environment Interaction Study of Breast Cancer in More than 90,000 Women. Cancer Research Communications, 2022, 2, 211-219.	0.7	6
10	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. Breast Cancer Research, 2022, 24, 27.	2.2	15
11	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Scientific Reports, 2022, 12, 6199.	1.6	2
12	Risk Assessment in Population-Based Breast Cancer Screening. Journal of Clinical Oncology, 2022, 40, 2279-2280.	0.8	8
13	Topical Endoxifen for Mammographic Density Reduction—A Randomized Controlled Trial. Oncologist, 2022, 27, e597-e600.	1.9	5
14	A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care. Science Translational Medicine, 2022, 14, eabn3971.	5.8	16
15	Towards implementation of comprehensive breast cancer risk prediction tools in health care for personalised prevention. Preventive Medicine, 2022, 159, 107075.	1.6	3
16	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	3.6	19
17	Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies. Journal of the National Cancer Institute, 2022, 114, 1706-1719.	3.0	14
18	Associations of a breast cancer polygenic risk score with tumor characteristics and survival Journal of Clinical Oncology, 2022, 40, 563-563.	0.8	1

#	Article	IF	CITATIONS
19	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	3.0	45
20	Impairment of endoxifen formation in tamoxifenâ€treated premenopausal breast cancer patients carrying reducedâ€function CYP2D6 alleles. British Journal of Clinical Pharmacology, 2021, 87, 1243-1252.	1.1	18
21	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	2.3	35
22	Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkaa087.	1.4	11
23	Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using populationâ€based cohort studies and twoâ€sample Mendelian randomization analyses. International Journal of Cancer, 2021, 148, 1338-1350.	2.3	9
24	Predictors of mammographic microcalcifications. International Journal of Cancer, 2021, 148, 1132-1143.	2.3	8
25	Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics: A populationâ€based cohort study. International Journal of Cancer, 2021, 148, 1351-1359.	2.3	4
26	Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns. International Journal of Cancer, 2021, 148, 884-894.	2.3	3
27	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	2.9	5
28	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
29	Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	13.9	532
30	Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?. Cancers, 2021, 13, 2370.	1.7	4
31	Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. JAMA Network Open, 2021, 4, e2114716.	2.8	14
32	Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. Journal of Clinical Oncology, 2021, 39, 1899-1908.	0.8	33
33	Mammographic microcalcifications and risk of breast cancer. British Journal of Cancer, 2021, 125, 759-765.	2.9	32
34	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	2.6	6
35	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	2.2	7
36	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	2.9	9

#	Article	IF	Citations
37	Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 2021, 596, 393-397.	13.7	183
38	Mammographic features are associated with cardiometabolic disease risk and mortality. European Heart Journal, 2021, 42, 3361-3370.	1.0	11
39	Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. Breast Cancer Research and Treatment, 2021, 190, 451-462.	1.1	1
40	Reply to T. Suemasu et al. Journal of Clinical Oncology, 2021, 39, 2966-2968.	0.8	0
41	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	1.1	19
42	Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women. Cancers, 2021, 13, 302.	1.7	7
43	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	1.6	2
44	Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients. Cancer Causes and Control, 2021, 32, 251-260.	0.8	12
45	The impact of COVID-19 Cleft Services in Great Britain & Northern Ireland. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2021, , .	0.5	2
46	Mammographic Density Change and Risk of Breast Cancer. Journal of the National Cancer Institute, 2020, 112, 391-399.	3.0	32
47	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
48	The impact of alcohol consumption and physical activity on breast cancer: The role of breast cancer risk. International Journal of Cancer, 2020, 147, 931-939.	2.3	14
49	CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. Journal of Clinical Oncology, 2020, 38, 548-557.	0.8	31
50	Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. Breast Cancer Research, 2020, 22, 101.	2.2	19
51	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
52	Hormonal determinants of mammographic density and density change. Breast Cancer Research, 2020, 22, 95.	2,2	20
53	Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors. BMC Medicine, 2020, 18, 225.	2.3	12
54	Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. Radiology, 2020, 297, 327-333.	3.6	40

#	Article	IF	CITATIONS
55	Aspirin and other non-steroidal anti-inflammatory drugs and depression, anxiety, and stress-related disorders following a cancer diagnosis: a nationwide register-based cohort study. BMC Medicine, 2020, 18, 238.	2.3	22
56	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
57	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology, 2020, 17, 687-705.	12.5	178
58	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	1.6	2
59	Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden. Breast, 2020, 53, 33-41.	0.9	12
60	European women's perceptions of the implementation and organisation of risk-based breast cancer screening and prevention: a qualitative study. BMC Cancer, 2020, 20, 247.	1.1	19
61	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nature Communications, 2020, 11 , 3353.	5.8	75
62	Inclusion of Endogenous Plasma Dehydroepiandrosterone Sulfate and Mammographic Density in Risk Prediction Models for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 574-581.	1.1	6
63	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
64	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	5.8	30
65	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Research and Treatment, 2020, 181, 423-434.	1.1	14
66	The association between breast cancer risk factors and background parenchymal enhancement at dynamic contrast-enhanced breast MRI. Acta Radiologica, 2020, 61, 1600-1607.	0.5	8
67	Heritability of Mammographic Breast Density, Density Change, Microcalcifications, and Masses. Cancer Research, 2020, 80, 1590-1600.	0.4	22
68	Profiles of histidine-rich glycoprotein associate with age and risk of all-cause mortality. Life Science Alliance, 2020, 3, e202000817.	1.3	9
69	Random effects tumour growth models for identifying image markers of mammography screening sensitivity. Epidemiologic Methods, 2020, 9, .	0.8	0
70	Sense of coherence and risk of breast cancer. ELife, 2020, 9, .	2.8	2
71	Disease trajectories and mortality among women diagnosed with breast cancer. Breast Cancer Research, 2019, 21, 95.	2.2	23
72	Interval breast cancer is associated with other types of tumors. Nature Communications, 2019, 10, 4648.	5.8	25

#	Article	IF	Citations
73	Association of Microcalcification Clusters with Short-term Invasive Breast Cancer Risk and Breast Cancer Risk Factors. Scientific Reports, 2019, 9, 14604.	1.6	24
74	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	1.6	5
75	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
76	Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study. Breast Cancer Research, 2019, 21, 8.	2.2	13
77	Does three-dimensional functional infrared imaging improve breast cancer detection based on digital mammography in women with dense breasts?. European Radiology, 2019, 29, 6227-6235.	2.3	8
78	Determinants of Mammographic Density Change. JNCI Cancer Spectrum, 2019, 3, pkz004.	1.4	27
79	Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. Breast Cancer Research, 2019, 21, 68.	2.2	31
80	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
81	Detection of potential microcalcification clusters using multivendor forâ€presentation digital mammograms for shortâ€term breast cancer risk estimation. Medical Physics, 2019, 46, 1938-1946.	1.6	11
82	Women's perceptions of personalized riskâ€based breast cancer screening and prevention: An international focus group study. Psycho-Oncology, 2019, 28, 1056-1062.	1.0	39
83	Cardiac Structure Doses in Women Irradiated for Breast Cancer in the Past and Their Use in Epidemiological Studies. Practical Radiation Oncology, 2019, 9, 158-171.	1.1	12
84	Comparison of self-reported and register-based hospital medical data on comorbidities in women. Scientific Reports, 2019, 9, 3527.	1.6	13
85	Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening. BMC Medicine, 2019, 17, 24.	2.3	7
86	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52
87	Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Research, 2019, 21, 144.	2.2	24
88	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants in a large, unselected breast cancer cohort. International Journal of Cancer, 2019, 144, 1195-1204.	2.3	31
89	The <i>BRCA2</i> c.68-7TÂ>ÂA variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	1.1	19
90	Towards Prevention of Breast Cancer: What Are the Clinical Challenges?. Cancer Prevention Research, 2018, 11, 255-264.	0.7	15

#	Article	IF	Citations
91	Genetic overlap between endometriosis and endometrial cancer: evidence from crossâ€disease genetic correlation and GWAS metaâ€analyses. Cancer Medicine, 2018, 7, 1978-1987.	1.3	62
92	A comprehensive tool for measuring mammographic density changes over time. Breast Cancer Research and Treatment, 2018, 169, 371-379.	1.1	45
93	Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. International Journal of Epidemiology, 2018, 47, 526-536.	0.9	88
94	Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density. Breast Cancer Research, 2018, 20, 14.	2.2	8
95	Long-term prognostic implications of risk factors associated with tumor size: a case study of women regularly attending screening. Breast Cancer Research, 2018, 20, 31.	2.2	10
96	Association of reproductive history with breast tissue characteristics and receptor status in the normal breast. Breast Cancer Research and Treatment, 2018, 170, 487-497.	1.1	15
97	Inclusion of Plasma Prolactin Levels in Current Risk Prediction Models of Premenopausal and Postmenopausal Breast Cancer. JNCI Cancer Spectrum, 2018, 2, pky055.	1.4	16
98	Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. Cancer Research, 2018, 78, 6329-6338.	0.4	19
99	Physical activity and mammographic density in an Asian multi-ethnic cohort. Cancer Causes and Control, 2018, 29, 883-894.	0.8	5
100	Inherited factors contribute to an inverse association between preeclampsia and breast cancer. Breast Cancer Research, 2018, 20, 6.	2.2	14
101	Common genetic variation and novel loci associated with volumetric mammographic density. Breast Cancer Research, 2018, 20, 30.	2.2	18
102	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	5.8	178
103	Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study. Breast Cancer Research, 2018, 20, 93.	2.2	5
104	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	9.4	184
105	Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects. Radiation Research, 2017, 186.	0.7	13
106	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.4	75
107	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nature Genetics, 2017, 49, 834-841.	9.4	426
108	Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients. Journal of the National Cancer Institute, 2017, 109, .	3.0	11

#	Article	IF	Citations
109	Assessment of Breast Cancer Risk Factors Reveals Subtype Heterogeneity. Cancer Research, 2017, 77, 3708-3717.	0.4	87
110	Cohort Profile: The Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA). International Journal of Epidemiology, 2017, 46, 1740-1741g.	0.9	88
111	A clinical model for identifying the short-term risk of breast cancer. Breast Cancer Research, 2017, 19, 29.	2.2	79
112	Breaking the matching in nested case–control data offered several advantages for risk estimation. Journal of Clinical Epidemiology, 2017, 82, 79-86.	2.4	6
113	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
114	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
115	Gene–environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. International Journal of Cancer, 2017, 141, 1830-1840.	2.3	20
116	Common shared genetic variation behind decreased risk of breast cancer in celiac disease. Scientific Reports, 2017, 7, 5942.	1.6	5
117	Differences in mammographic density between Asian and Caucasian populations: a comparative analysis. Breast Cancer Research and Treatment, 2017, 161, 353-362.	1.1	61
118	Longitudinal fluctuation in mammographic percent density differentiates between interval and screenâ€detected breast cancer. International Journal of Cancer, 2017, 140, 34-40.	2.3	6
119	Comparison of handheld ultrasound and automated breast ultrasound in women recalled after mammography screening. Acta Radiologica, 2017, 58, 515-520.	0.5	22
120	Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. Clinical Cancer Research, 2017, 23, 2584-2592.	3.2	15
121	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genetics in Medicine, 2017, 19, 599-603.	1.1	67
122	Timeâ€dependent risk and predictors of venous thromboembolism in breast cancer patients: A populationâ€based cohort study. Cancer, 2017, 123, 468-475.	2.0	31
123	<scp>T</scp> imeâ€dependent risk of depression, anxiety, and stressâ€related disorders in patients with invasive and <i>in situ</i> i> breast cancer. International Journal of Cancer, 2017, 140, 841-852.	2.3	59
124	Cause-specific mortality in women with breast cancer <i>in situ</i> . International Journal of Cancer, 2017, 140, 2414-2421.	2.3	13
125	Associations between childhood body size and seventeen adverse outcomes: analysis of 65,057 European women. Scientific Reports, 2017, 7, 16917.	1.6	8
126	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	0.9	45

#	Article	IF	Citations
127	Risk and predictors of psoriasis in patients with breast cancer: a Swedish population-based cohort study. BMC Medicine, 2017, 15, 154.	2.3	13
128	Breast Tissue Organisation and its Association with Breast Cancer Risk. Breast Cancer Research, 2017, 19, 103.	2.2	11
129	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. Breast Cancer Research, 2017, 19, 119.	2.2	43
130	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget, 2017, 8, 18381-18398.	0.8	14
131	<i>PHIP</i> - a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 2017, 8, 102769-102782.	0.8	9
132	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 2016, 7, 80140-80163.	0.8	31
133	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Medicine, 2016, 13, e1002105.	3.9	118
134	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	1.1	12
135	Amount of stroma is associated with mammographic density and stromal expression of oestrogen receptor in normal breast tissues. Breast Cancer Research and Treatment, 2016, 158, 253-261.	1.1	17
136	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	2.3	51
137	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
138	Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association Consortium. Breast Cancer Research, 2016, 18, 98.	2.2	39
139	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
140	Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry. Breast Cancer Research, 2016, 18, 124.	2.2	52
141	Association of infertility and fertility treatment with mammographic density in a large screening-based cohort of women: a cross-sectional study. Breast Cancer Research, 2016, 18, 36.	2.2	12
142	Infection-related hospitalizations in breast cancer patients: Risk and impact on prognosis. Journal of Infection, 2016, 72, 650-658.	1.7	22
143	Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Research, 2016, 18, 22.	2.2	43
144	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	0.8	21

#	Article	IF	CITATIONS
145	Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics, 2016, 48, 667-674.	9.4	77
146	Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. British Journal of Cancer, 2016, 115, 1400-1407.	2.9	22
147	Novel mammographic image features differentiate between interval and screen-detected breast cancer: a case-case study. Breast Cancer Research, 2016, 18, 100.	2.2	17
148	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	2.6	59
149	Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: A crossâ€sectional study. International Journal of Cancer, 2016, 139, 2415-2425.	2.3	23
150	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 2016, 25, 3863-3876.	1.4	33
151	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1503-1510.	1.1	64
152	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. Scientific Reports, 2016, 6, 36874.	1.6	2
153	Increased pancreatic cancer risk following radiotherapy for testicular cancer. British Journal of Cancer, 2016, 115, 901-908.	2.9	30
154	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
155	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5. 8	93
156	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5. 8	78
157	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 2016, 6, 32512.	1.6	19
158	Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients. Clinical Cancer Research, 2016, 22, 5249-5255.	3.2	12
159	Common diseases as determinants of menopausal age. Human Reproduction, 2016, 31, 2856-2864.	0.4	42
160	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocrine-Related Cancer, 2016, 23, 77-91.	1.6	62
161	The HLA-DQβ1 insertion is a strong achalasia risk factor and displays a geospatial north–south gradient among Europeans. European Journal of Human Genetics, 2016, 24, 1228-1231.	1.4	21
162	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Human Molecular Genetics, 2016, 25, 2256-2268.	1.4	106

#	Article	IF	CITATIONS
163	No evidence that protein truncating variants in <i>BRIP1</i> ii>are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	1.5	94
164	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
165	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Human Genetics, 2016, 135, 137-154.	1.8	8
166	Associations of Breast Cancer Risk Prediction Tools With Tumor Characteristics and Metastasis. Journal of Clinical Oncology, 2016, 34, 251-258.	0.8	45
167	Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer. Acta Oncol \tilde{A}^3 gica, 2016, 55, 45-51.	0.8	39
168	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
169	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	1.1	26
170	Investigation of geneâ€environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. International Journal of Cancer, 2015, 136, E685-96.	2.3	34
171	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports, 2015, 5, 17369.	1.6	35
172	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. BMC Cancer, 2015, 15, 978.	1.1	6
173	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	2.2	26
174	Identification of two novel mammographic density loci at 6Q25.1. Breast Cancer Research, 2015, 17, 75.	2.2	24
175	Breast cancer tumour growth modelling for studying the association of body size with tumour growth rate and symptomatic detection using case-control data. Breast Cancer Research, 2015, 17, 116.	2.2	14
176	A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. Breast Cancer Research, 2015, 17, 110.	2.2	19
177	The Genetic Basis of Quality of Life in Healthy Swedish Women: A Candidate Gene Approach. PLoS ONE, 2015, 10, e0118292.	1.1	8
178	The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genetics, 2015, 11, e1005378.	1.5	331
179	SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival. Oncotarget, 2015, 6, 37979-37994.	0.8	20
180	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	3.0	428

#	Article	IF	Citations
181	Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206.	13.7	3,823
182	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	1.4	40
183	Risk Factors and Tumor Characteristics of Interval Cancers by Mammographic Density. Journal of Clinical Oncology, 2015, 33, 1030-1037.	0.8	99
184	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	2.6	76
185	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	1.3	14
186	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	9.4	513
187	Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer. Journal of Clinical Oncology, 2015, 33, 2262-2269.	0.8	78
188	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	2.6	37
189	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	3.0	56
190	Pectoral Muscle Attenuation as a Marker for Breast Cancer Risk in Full-Field Digital Mammography. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 985-991.	1.1	6
191	Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. Clinical Proteomics, 2015, 12, 8.	1.1	31
192	Background risk of breast cancer and the association between physical activity and mammographic density. Breast Cancer Research, 2015, 17, 50.	2.2	17
193	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. Cancer Research, 2015, 75, 2457-2467.	0.4	55
194	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303.	9.4	357
195	Effects of statin use on volumetric mammographic density: results from the KARMA study. BMC Cancer, 2015, 15, 435.	1.1	7
196	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	3.0	99
197	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocrine-Related Cancer, 2015, 22, 851-861.	1.6	25
198	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	1.1	24

#	Article	IF	Citations
199	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	1.4	38
200	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492.	1.4	50
201	In Search for the Genetic Basis of Quality of Life in Healthy Swedish Women—A GWAS Study Using the iCOGS Custom Genotyping Array. PLoS ONE, 2015, 10, e0140563.	1.1	2
202	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget, 2015, 6, 7390-7407.	0.8	15
203	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	1.1	49
204	Area and Volumetric Density Estimation in Processed Full-Field Digital Mammograms for Risk Assessment of Breast Cancer. PLoS ONE, 2014, 9, e110690.	1.1	24
205	Automated Measurement of Volumetric Mammographic Density: A Tool for Widespread Breast Cancer Risk Assessment. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1764-1772.	1.1	62
206	Volumetric Mammographic Density: Heritability and Association With Breast Cancer Susceptibility Loci. Journal of the National Cancer Institute, 2014, 106, dju334-dju334.	3.0	21
207	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	1.5	39
208	Enhancement of Mammographic Density Measures in Breast Cancer Risk Prediction. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1314-1323.	1.1	17
209	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051.	5.8	16
210	Genomic Diversity and Admixture Differs for Stone-Age Scandinavian Foragers and Farmers. Science, 2014, 344, 747-750.	6.0	315
211	Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Geneâ€Environment Interactions. Genetic Epidemiology, 2014, 38, 84-93.	0.6	28
212	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nature Communications, 2014, 5, 5303.	5.8	109
213	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 2014, 514, 92-97.	13.7	548
214	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	5.8	105
215	Defining the role of common variation in the genomic and biological architecture of adult human height. Nature Genetics, 2014, 46, 1173-1186.	9.4	1,818
216	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	2.2	14

#	Article	IF	CITATIONS
217	Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. Haematologica, 2014, 99, e193-e196.	1.7	37
218	Evaluation of Exome Sequencing to Estimate Tumor Burden in Plasma. PLoS ONE, 2014, 9, e104417.	1.1	25
219	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	2.6	98
220	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
221	Change of mammographic density predicts the risk of contralateral breast cancer - a case-control study. Breast Cancer Research, 2013, 15, R57.	2.2	44
222	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	2.6	201
223	Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	9.4	374
224	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	9.4	960
225	Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer. New England Journal of Medicine, 2013, 368, 987-998.	13.9	3,028
226	A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication. Breast Cancer Research and Treatment, 2013, 138, 529-542.	1.1	18
227	Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome–wide interaction study. Endocrine-Related Cancer, 2013, 20, 875-887.	1.6	26
228	Mammographic Density Reduction Is a Prognostic Marker of Response to Adjuvant Tamoxifen Therapy in Postmenopausal Patients With Breast Cancer. Journal of Clinical Oncology, 2013, 31, 2249-2256.	0.8	113
229	Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284.	1.5	136
230	Influence of Lifestyle Factors on Mammographic Density in Postmenopausal Women. PLoS ONE, 2013, 8, e81876.	1.1	37
231	Stomach cancer risk following radiotherapy for testicular cancer Journal of Clinical Oncology, 2013, 31, 4536-4536.	0.8	9
232	Common Breast Cancer Susceptibility Variants in <i>LSP1</i> and <irad51l1< i=""> Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1156-1166.</irad51l1<>	1.1	101
233	Mammographic Breast Density and Breast Cancer: Evidence of a Shared Genetic Basis. Cancer Research, 2012, 72, 1478-1484.	0.4	54
234	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	1.4	152

#	Article	IF	Citations
235	Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nature Genetics, 2011, 43, 185-187.	9.4	109
236	A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Research and Treatment, 2011, 126, 717-727.	1.1	90
237	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research, 2010, 12, R110.	2.2	82
238	Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010, 42, 937-948.	9.4	2,634
239	Risk of Treatment-Related Stomach Cancer Among Hodgkin Lymphoma Survivors. Blood, 2010, 116, 2679-2679.	0.6	0
240	Association of ESR1 gene tagging SNPs with breast cancer risk. Human Molecular Genetics, 2009, 18, 1131-1139.	1.4	84
241	Cardiac doses from Swedish breast cancer radiotherapy since the 1950s. Radiotherapy and Oncology, 2009, 90, 127-135.	0.3	87
242	Radiation-associated urinary bladder cancer. Scandinavian Journal of Urology and Nephrology, 2008, 42, 85-88.	1.4	15
243	Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Research, 2006, 8, R34.	2.2	218
244	Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Medicine, 2006, 4, 16.	2.3	47
245	Effect of low doses of ionising radiation in infancy on cognitive function in adulthood: Swedish population based cohort study. BMJ: British Medical Journal, 2004, 328, 19-0.	2.4	280
246	Thyroid cancer risk after thyroid examination with 1311: A population-based cohort study in Sweden. International Journal of Cancer, 2003, 106, 580-587.	2.3	112
247	Incidence and survival of Swedish patients with differentiated thyroid cancer. International Journal of Cancer, 2003, 106, 569-573.	2.3	71
248	Treatment-Associated Leukemia Following Testicular Cancer. Journal of the National Cancer Institute, 2000, 92, 1165-1171.	3.0	225
249	Radiation-Associated Thyroid Cancer - Facts and Fiction. Acta Oncol $ ilde{A}^3$ gica, 1998, 37, 325-330.	0.8	31
250	Increased Risk of Second Primary Malignancies in Patients with Gynecological Cancer: A Swedish record-linkage study. Acta Oncol \tilde{A}^3 gica, 1995, 34, 771-777.	0.8	45
251	Non-Hodgkin's lymphoma and skin malignancies-shared etiology?. International Journal of Cancer, 1995, 62, 519-522.	2.3	64
252	Cancer Incidence and Mortality after Iodine-131 Therapy for Hyperthyroidism. Advances in Chemistry Series, 1995, , 103-112.	0.6	0

#	Article	lF	CITATIONS
253	Tumors after Radiotherapy for Thyroid Cancer; A case-control study within a cohort of thyroid cancer patients. Acta Oncol \tilde{A}^3 gica, 1992, 31, 403-407.	0.8	28
254	Cancer mortality after iodine-131 therapy for hyperthyroidism. International Journal of Cancer, 1992, 50, 886-890.	2.3	107
255	Radiation-induced thyroid cancer. Medical Oncology and Tumor Pharmacotherapy, 1992, 9, 183-189.	1.0	8
256	Implantable catheter system for long-term intravenous chemotherapy. Journal of Surgical Oncology, 1989, 41, 39-41.	0.8	32